Acta Scientific Neurology (ASNE) (ISSN: 2582-1121)

Research Article Volume 3 Issue 10

Deregulated Homocysteine Metabolism in Friedreich’s Ataxia Patients: A Risk Factor?

Deepti Pathak1, Achal K Srivastava2, Sheffali Gulati3 and Moganty R Rajeswari1*

1Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India
2Department of Neurology, All India Institute of Medical Sciences, New Delhi, India
3Department of Paediatrics, All India Institute of Medical Science, New Delhi, India

*Corresponding Author: Moganty R Rajeswari, Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.

Received: September 11, 2020; Published: September 26, 2020



  Friedreich's ataxia (FRDA) is a progressive neurodegenerative disorder primarily caused by sub-optimal levels of mitochondrial protein, frataxin, and is characterized by hypersensitivity to oxidative stress. Homocysteine (Hcy) is well acknowledged to mediate oxidative stress-induced toxicity and mitochondrial dysfunction in pathogenesis of several cardiovascular and neurological diseases. Here, we tried to explore the correlation between plasma Hcy levels with various biochemical, genetic and clinical parameters in FRDA. Assessment of Hcy levels in blood plasma of FRDA patients (N = 25) and healthy controls (N = 25) showed that mean levels of Hcy were significantly elevated (9.78 ± 2.7 μmol/l) in FRDA as compared to those of controls (7.0 ± 2.05 μmol/l). The clinical severity of FRDA, as reflected by the (GAA) expansion number in DNA (extent of genetic error), the decreased levels of frataxin protein (primary pathogenic marker), longer disease duration and the high score of Friedreich's Ataxia Rating Scale (measure of neuromuscular activity) revealed positive correlation with plasma Hcy levels in FRDA patients. As deficiency of Vitamin B12 is linked to hyperhomocysteinemia, we analyzed the plasma Vitamin B12 levels and found an inverse correlation with those of Hcy, which supports their deregulated metabolic homeostasis in FRDA. Present results highlight the association of Hcy with the pathogenesis of FRDA thus suggesting Hcy as a potential biomarker for disease progression and/therapeutic intervention.

Keywords: Friedreich's Ataxia (FRDA); Homocysteine; Vitamin B12; Oxidative Stress; Neurodegeneration



  1. Abrahão A., et al. “Milestones in Friedreich ataxia: more than a century and still learning”. Neurogenetics. Springer Verlag 16 (2015): 151-160.
  2. Selvadurai LP., et al. “Cerebral abnormalities in Friedreich ataxia: A review”. Neuroscience and Biobehavioral Reviews 84 (2018): 394-406.
  3. Delatycki MB., et al. “Friedreich ataxia: an overview”. (2000): 1-8.
  4. Pandolfo M and Pastore A. “The pathogenesis of Friedreich ataxia and the structure and function of frataxin”. Journal of Neurology 256 (2009): 9-17.
  5. Campuzano V., et al. “Friedreich’s ataxia: Autosomal recessive disease caused by an intronic GAA triplet repeat expansion”. Science 5254 (1996): 1423-1427.
  6. Martelli A and Puccio H. “Dysregulation of cellular iron metabolism in Friedreich ataxia: from primary iron-sulfur cluster deficit to mitochondrial iron accumulation”. Frontiers in Pharmacology 5 (2014): 1-11.
  7. Gomes CM and Santos R. “Neurodegeneration in Friedreich’s Ataxia: From Defective Frataxin to Oxidative Stress”. Oxidative Medicine and Cellular Longevity 2013 (2013).
  8. Li K., et al. “Expression of Human Frataxin Is Regulated by Transcription Factors SRF and TFAP2”. Plos One8 (2010): 1-8.
  9. Lodi R., et al. “Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia”. Proceedings of the National Academy of Sciences of the United States of America 96 (1999).
  10. Shidara Y and Hollenbeck PJ. “Defects in Mitochondrial Axonal Transport and Membrane Potential without Increased Reactive Oxygen Species Production in a Drosophila Model of Friedreich Ataxia”. Journal of Neuroscience34 (2010): 11369-11378.
  11. Melo A., et al. “Oxidative Stress in Neurodegenerative Diseases: Mechanisms and Therapeutic Perspectives”. Oxidative Medicine and Cellular Longevity (2011).
  12. Abeti R., et al. “Mitochondrial energy imbalance and lipid peroxidation cause cell death in Friedreich’s ataxia”. Cell Death and Disease5 (2016): e2237.
  13. Determinants I. 5th Amino Acid Assessment Workshop The Hordaland Homocysteine Study: A Community-Based Study of Homocysteine, Its Determinants, and Associations with Disease 1. Child and Adolescent Mental Health (2006).
  14. Boldyrev AA. “Why homocysteine is a risk factor of neurodegenerative diseases mini review”. Neurochemistry Journal1 (2007): 14-20.
  15. Levin M., et al. “Neurodegeneration in multiple sclerosis involves multiple pathogenic mechanisms”. Degenerative Neurological and Neuromuscular Disease 4 (2014): 49-63.
  16. Obeid R and Herrmann W. “Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia”. FEBS Letter13 (2006): 2994-3005.
  17. Lehotsky J., et al. “Mechanisms Involved in the Ischemic Tolerance in Brain: Effect of the Homocysteine”. Cellular and Molecular Neurobiology 1 (2015): 7-15.
  18. Mattson MP and Shea TB. “Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders”. Trends in Neuroscience3 (2003): 137-146.
  19. Altun H., et al. “Homocysteine, Pyridoxine, Folate and Vitamin B12 Levels in Children With Attention Deficit Hyperactivity Disorder”. Psychiatria Danubina 3 (2108): 310-316.
  20. Wu X., et al. “Homocysteine causes vascular endothelial dysfunction by disrupting endoplasmic reticulum redox homeostasis”. Redox Biology 20 (2019): 46-59.
  21. Zoccolella S., et al. “Elevated plasma homocysteine levels in patients with amyotrophic lateral sclerosis”. Neurology3 (2008): 222-225.
  22. Lynch DR., et al. “Measuring Friedreich ataxia performance measures”. (2006).
  23. Swarup V., et al. “Circulating (cell-free) nucleic acids - A promising, non-invasive tool for early detection of several human diseases”. FEBS Letters 581 (2006): 795-799.
  24. Swarup V., et al. “Quantitative profiling and identification of differentially expressed plasma proteins in friedreich’s ataxia”. Journal of Neuroscience Research11 (2013): 1483-1491.
  25. Dantham S., et al. “Differentially Regulated Cell-Free MicroRNAs in the Plasma of Friedreich’s Ataxia Patients and Their Association with Disease Pathology”. Neuropediatrics1 (2018): 35-43.
  26. Dantham S., et al. “Plasma circulating cell-free mitochondrial DNA in the assessment of Friedreich’s ataxia”. Journal of the Neurological Sciences (2016).
  27. Dantham S., et al. “Differentially Regulated Cell-Free MicroRNAs in the Plasma of Friedreich’s Ataxia Patients and Their Association with Disease Pathology”. Neuropediatrics1 (2018): 35-43.
  28. Bulteau AL., et al. “Changes in mitochondrial glutathione levels and protein thiol oxidation in Δyfh1 yeast cells and the lymphoblasts of patients with Friedreich’s ataxia”. Biochimica et Biophysica Acta - Molecular Basis of Disease2 (2012): 212-225.
  29. Lu C., et al. “Frataxin deficiency induces Schwann cell inflammation and death”. Biochimica et Biophysica Acta 1792 (2009): 1052-1061.
  30. Rotig A., et al. “Aconitase and mitochondrial iron-sulphur protein deficiency in friedreich ataxia”. Nature Genetics2 (1997): 215-217.
  31. Karthikeyan G., et al. “Reduction in frataxin causes progressive accumulation of mitochondrial damage”. Human Molecular Genetics (2003).
  32. McCaddon A and Miller JW. “Assessing the association between homocysteine and cognition: Reflections on Bradford Hill, meta-analyses, and causality”. Nutrition Review10 (2015): 723-735.
  33. Clarke R., et al. “Folate, vitamin b12, and serum total homocysteine levels in confirmed alzheimer disease”. Archives of Neurology11 (1998): 1449-1455.
  34. Morris MS. “Homocysteine and Alzheimer’s disease”. Lancet Neurology7 (2003): 425-428.
  35. Lehotskỳ J., et al. “Role of homocysteine in the ischemic stroke and development of ischemic tolerance”. Frontiers in Neuroscience 10 (2016): 1-16.
  36. Weiss N., et al. “Influence of Hyperhomocysteinemia on the Cellular Redox State - Impact on Homocysteine-Induced Endothelial Dysfunction”. Clinical Chemistry and Laboratory Medicine 11 (2003): 1455-1461.
  37. Vitvitsky V., et al. “Redox regulation of homocysteine-dependent glutathione synthesis”. Redox Report1 (2003): 57-63.
  38. Perna AF., et al. “Possible mechanisms of homocysteine toxicity”. Kidney International 63 (2003): S137-140.
  39. Moustafa AA., et al. “Homocysteine levels in schizophrenia and affective disorders—focus on cognition”. Frontiers in Behavioral Neuroscience 8 (2014): 1-10.
  40. STUART A LIPTON., et al. “Neurotoxicity associated with dual actions of homocysteine at the N-methyl-d-aspartate receptor”. Proceedings of the National Academy of Sciences of the United States of America 94 (1997): 5923-5928.
  41. Ho PI., et al. “Multiple aspects of homocysteine neurotoxicity: Glutamate excitotoxicity, kinase hyperactivation and DNA damage”. Journal of Neuroscience Research 5 (2002): 694-702.


Citation: Moganty R Rajeswari., et al. “Deregulated Homocysteine Metabolism in Friedreich’s Ataxia Patients: A Risk Factor?". Acta Scientific Neurology 3.10 (2020): 39-47.


Acceptance rate32%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US